Re: 6%

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: 6%

in response to

Re: 6%

KayakerBC

posted on Dec 15, 2022 10:55AM

KBC, that would be the 6% Royalty steam paid to ZCC generated from the revenue that would come from successful ZEN-3694 in collaboration with BPs drugs. (vis-a-vis trials that are presently ongoing)